Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10506137 | 0.85 | MEN1 (0.58) | MEN1KMT2APOLBBLMTDP1 | |
| SCHEMBL11216007 | 0.82 | MEN1 (0.49) | MEN1KMT2APOLBBLMTDP1 | |
| SCHEMBL3854415 | 0.82 | ALOX15 (0.61) | MEN1KMT2AMAPTTBXAS1ALDH1A1 | |
| SCHEMBL3371954 | 0.82 | MEN1 (0.51) | MEN1KMT2APOLBBLMTDP1 | |
| SCHEMBL1480561 | 0.81 | RXRA (0.53) | KMT2ARAB9AMAPTKDM4EALDH1A1 | |
| SCHEMBL14546296 | 0.81 | MEN1 (0.47) | MEN1KMT2APOLBBLMTDP1 | |
| SCHEMBL1432953 | 0.80 | POLB (0.54) | MEN1KMT2APOLBBLMTDP1 | |
| SCHEMBL23582938 | 0.79 | PLA2G4B (0.55) | MEN1KMT2ARAB9ATP53MAPT | |
| SCHEMBL8138470 | 0.79 | MAOB (0.50) | MEN1KMT2APOLBBLMTDP1 | |
| SCHEMBL1662603 | 0.79 | PPARG (0.44) | MEN1KMT2ATP53MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168170-A1 | Piperidinones Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2010-07-01 | — | — | US | disclosed |
| EP-2137150-A1 | PIPERIDINONES USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008110794-A1 | PIPERIDINONES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168170-A1 | Piperidinones Useful in the Treatment of Inflammation | ARG1, ARG2, PRMT1 | MEN1 2722/4885KMT2A 1178/4885POLB 1293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.